Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stephen K. Doberstein
Bempegaldesleukin (NKTR-214): A CD-122-biased IL-2 Receptor Agonist for Cancer Immunotherapy
Expert Opinion on Biological Therapy
Drug Discovery
Clinical Biochemistry
Pharmacology
Related publications
Efficacy and Immune Modulation of the Tumor Microenvironment With the Combination of the PARP Inhibitor Rucaparib and CD122-biased Agonist NKTR-214.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Prospects of IL-2 in Cancer Immunotherapy
BioMed Research International
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
214. Design of Multifunctional Chimeric Antigen Receptors for T Cell Cancer Immunotherapy
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Characterization of Methadone as a Β-Arrestin-Biased Μ-Opioid Receptor Agonist
Molecular Pain
Molecular Medicine
Anesthesiology
Pain Medicine
Cellular
Molecular Neuroscience
Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
Frontiers in Immunology
Allergy
Immunology
IL-2; IL-2 Receptor Α-Chain (IL2-RA; CD25); IL-2 Receptor Β-Chain (IL2-RB; CD122)
Science-Business eXchange
Agonist-Biased Signaling via Proteinase Activated Receptor-2: Differential Activation of Calcium and Mitogen-Activated Protein Kinase Pathways
Molecular Pharmacology
Molecular Medicine
Pharmacology
403. The Potential of Pro-Apoptotic PAC-1 Treatment for Augmentation of IL-2 Mediated Breast Cancer Immunotherapy
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Interleukin 2 (IL-2) Augments Transcription of the IL-2 Receptor Gene.
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
